ECM
GNCA

ExodusPoint Capital Management’s Genocea Biosciences, Inc. GNCA Stock Holding History

ExodusPoint Capital Management’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-11,131
Closed -$26K – 2929
2021
Q2 		$26K Sell
11,131
-100
-0.9% -$241 ﹤0.01% 2252
2021
Q1 		$30K Buy
+11,231
New +$33.3K ﹤0.01% 2051

Other funds holding GNCA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ExodusPoint Capital Management's GNCA Position: Q3 2021 in Review

ExodusPoint Capital Management sold out of Genocea Biosciences, Inc. (GNCA) in Q3 2021, closing a stake of 11,131 shares — an estimated $26K sold.

ExodusPoint Capital Management first reported a position in GNCA in Q1 2021 and held it in 2 quarters. The position peaked at $30K in Q1 2021. 40 funds tracked by Wall St. Rank hold GNCA as of Q3 2021.

  • ExodusPoint Capital Management reported no remaining Genocea Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
  • ExodusPoint Capital Management sold 11,131 Genocea Biosciences, Inc. shares in Q3 2021, an estimated $26K.
  • ExodusPoint Capital Management first reported a position in Genocea Biosciences, Inc. in Q1 2021 and held it in 2 quarters.
  • ExodusPoint Capital Management's Genocea Biosciences, Inc. position peaked at $30K in Q1 2021.
  • 40 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q3 2021.

Based on ExodusPoint Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.